A Phase I/Ib Study Evaluating GDC-0077 (inavolisib) + Palbociclib (palbo) + Fulvestrant in Patients (pts) with PIK3CA-mutant (mut), Hormone Receptor-Positive/her2-negative Metastatic Breast Cancer (HR+/HER2- Mbc)
Senologie - Zeitschrift für Mammadiagnostik und -therapie(2021)
AI 理解论文
溯源树
样例

生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要